Table 1.
Average mass reduction of Igrov1/T8 xenografts after various routes of combination drug administration with and without accounting for fibrosis
| Administration Route | Dosage |
N | Average Mass Reduction after 96 hours (%) | SEM | P-value | |||
|---|---|---|---|---|---|---|---|---|
| TPT | CID44640177 | CID1434724 | CID46245505 | |||||
| IT | 100 nM | 100 nM | 9 | 64 | 8.01 | <0.01 | ||
| 100 nM | 500 nM | 8 | 66 | 8.83 | <0.01 | |||
| 100 nM | 100 nM | 6 | 62 | 8.54 | <0.01 | |||
| RO | 100 nM | 1 μM | 4 | 13 | 4.52 | 0.04 | ||
| 100 nM | 1 μM | 4 | 14 | 15.92 | 0.42 | |||
| 100 nM | 1 μM | 5 | 2 | 7.31 | 0.78 | |||
| IP | 300 nM | 100 nM | 5 | 16 | 1.08 | <0.01 | ||
| 300 nM | 500 nM | 3 | 52 | 11.06 | 0.01 | |||
| 300 nM | 100 nM | 3 | 69 | 10.33 | <0.01 | |||
| Administration Route | Dosage |
N | Average Reduction after 96 hours adjusted for Fibrosis of Remaining Mass (%) | SEM | P-value | |||
|---|---|---|---|---|---|---|---|---|
| TPT | CID44640177 | CID1434724 | CID46245505 | |||||
| IT | 100 nM | 100 nM | 8 | 71 | 7.24 | <0.01 | ||
| 100 nM | 500 nM | 8 | 80 | 7.69 | <0.01 | |||
| 100 nM | 100 nM | 8 | 72 | 6.11 | <0.01 | |||
| RO | 100 nM | 1 μM | 4 | 51 | 4.98 | <0.01 | ||
| 100 nM | 1 μM | 5 | 35 | 9.67 | 0.01 | |||
| 100 nM | 1 μM | 5 | 27 | 11.24 | 0.04 | |||
| IP | 300 nM | 100 nM | 5 | 51 | 7.44 | <0.01 | ||
| 300 nM | 500 nM | 3 | 77 | 4.86 | <0.01 | |||
| 300 nM | 100 nM | 3 | 74 | 10.66 | <0.01 | |||